An ophthalmology expert provides an overview of biosimilars and their potential in ophthalmology practices.
Back
Utilization of Biosimilars in Retinal Diseases
Dr Peter Kaiser, an ophthalmologist, provides an overview of biosimilars, the regulatory pathway for their approval, and how biosimilars can aid in providing quality care to patients. Dr. Kaiser shares data with ranibizumab biosimilars in ophthalmology and discusses key differences between biosimilar and reference product studies.
Utilization of Biosimilars in Retinal Diseases
Episodes
All
All
Dr Peter Kaiser outlines approval process of biosimilars and highlights key differences from approval process of reference products.
Dr Kaiser shares critical differences in primary outcome readout in clinical studies for biosimilars vs reference products for retinal diseases.
Dr Peter Kaiser provides an overview of biosimilars that are either approved or are being developed for treatment of retinal diseases.
An ophthalmologist discusses challenges and concerns that physicians might face when using biosimilars for retinal diseases.
Dr Peter Kaiser shares helpful hints for patient communication and for including biosimilars in clinical practice.
Advertisement
Advertisement
Trending on HCPLive
1
AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD
2
What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MD
3
ESC 2026 Recap: 5 Practice-Changing Trials to Know
4
Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study
5